{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:00:55Z","timestamp":1792695655697,"version":"4.5.0"},"reference-count":71,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immunotherapy has revolutionized the treatment paradigms of several cancer types, yet only a subset of patients derives durable clinical benefit. Ferroptosis is a programmed cell death facilitated by iron-driven overload of lipid peroxidation. We aimed to evaluate ferroptosis activity based on tumor transcriptomic profiles to determine its predictive value for immunotherapy outcomes. We analyzed RNA sequencing data from eight independent cohorts of patients with urothelial, gastric, skin, and lung cancers treated with immune checkpoint inhibitors or adoptive T-cell therapy. A ferroptosis activity model was constructed using downstream gene expression signatures. Associations with overall survival and progression-free survival were assessed. Potential mechanisms were explored by examining immunosenescence, the IFN-\u03b3 immune response pathway, and immunogenic cell death. Ferroptosis-high tumors were associated with significantly improved overall survival and progression-free survival across multiple cancer types. Integrating ferroptosis scores with tumor mutation burden, liver metastasis status, and immune microenvironment phenotypes (inflamed, excluded, desert) enhanced patient stratification and predictive accuracy. Mechanistically, ferroptosis enhanced the immune response by promoting immunogenic cell death and attenuating immunosenescence. In conclusion, elevated ferroptosis activity correlates with improved immunotherapy outcomes, potentially through increased tumor immunogenicity and reduced immunosenescence. Ferroptosis-based biomarkers may aid in identifying patients more likely to benefit from immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Ferroptosis, an iron-dependent cell death process, is linked to improved immunotherapy outcomes. In this real-world study across eight cohorts, ferroptosis-high tumors showed 2 to 3 times longer survival. Mechanistically, ferroptosis enhanced immunogenicity and suppressed immunosenescence, highlighting its potential as a biomarker and therapeutic target to boost immunotherapy efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0268","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:38:00Z","timestamp":1753184280000},"page":"1288-1297","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2226-2223","authenticated-orcid":false,"given":"Zhijun","family":"Zhou","sequence":"first","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."},{"name":"2Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3428-1855","authenticated-orcid":false,"given":"Yang","family":"Cai","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."},{"name":"2Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4848-3354","authenticated-orcid":false,"given":"Hao","family":"Yuan","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."},{"name":"2Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1782-6999","authenticated-orcid":false,"given":"Qun","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."},{"name":"2Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1400-7061","authenticated-orcid":false,"given":"Sophia W.","family":"Zhao","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3265-161X","authenticated-orcid":false,"given":"Jingxuan","family":"Yang","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."},{"name":"2Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9121-2591","authenticated-orcid":false,"given":"Mingyang","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."},{"name":"2Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8854-2295","authenticated-orcid":false,"given":"Alex X.","family":"Arreola","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."},{"name":"3Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-5209","authenticated-orcid":false,"given":"Yu","family":"Ren","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."},{"name":"2Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-6187","authenticated-orcid":false,"given":"Chao","family":"Xu","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics and Epidemiology, Hudson College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6756-129X","authenticated-orcid":false,"given":"Lacey R.","family":"McNally","sequence":"additional","affiliation":[{"name":"2Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8770-0872","authenticated-orcid":false,"given":"Michael S.","family":"Bronze","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2487-5242","authenticated-orcid":false,"given":"Courtney W.","family":"Houchen","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2849-5450","authenticated-orcid":false,"given":"Kuirong","family":"Jiang","sequence":"additional","affiliation":[{"name":"5Pancreas Center, The Frist Affiliated Hospital of Nanjing Medical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7133-5794","authenticated-orcid":false,"given":"Wei R.","family":"Chen","sequence":"additional","affiliation":[{"name":"6Stephenson School of Biomedical Engineering, The University of Oklahoma, Norman, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8839-4849","authenticated-orcid":false,"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."},{"name":"2Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3971-9130","authenticated-orcid":false,"given":"Min","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."},{"name":"2Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"2025080607064794600_bib1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"2025080607064794600_bib2","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"2025080607064794600_bib3","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2025080607064794600_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"2025080607064794600_bib5","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41571-024-00955-2","article-title":"Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response","volume":"21","author":"Williams","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2025080607064794600_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"2025080607064794600_bib7","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s43018-020-00139-8","article-title":"Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy","volume":"1","author":"Samstein","year":"2021","journal-title":"Nat Cancer"},{"key":"2025080607064794600_bib8","doi-asserted-by":"crossref","first-page":"e2100267","DOI":"10.1200\/PO.21.00267","article-title":"Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers","volume":"6","author":"Garmezy","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2025080607064794600_bib9","doi-asserted-by":"crossref","first-page":"e217728","DOI":"10.1001\/jamanetworkopen.2021.7728","article-title":"Evaluation of BRCA1 and BRCA2 as indicators of response to immune checkpoint inhibitors","volume":"4","author":"Zhou","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025080607064794600_bib10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.annonc.2024.03.009","article-title":"Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer","volume":"35","author":"Ambrosini","year":"2024","journal-title":"Ann Oncol"},{"key":"2025080607064794600_bib11","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","article-title":"Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025080607064794600_bib12","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2025080607064794600_bib13","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"2025080607064794600_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"2025080607064794600_bib15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"2025080607064794600_bib16","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of immunotherapy combination strategies in cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"2025080607064794600_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccell.2023.12.008","article-title":"Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy","volume":"42","author":"Wienke","year":"2024","journal-title":"Cancer Cell"},{"key":"2025080607064794600_bib18","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"2025080607064794600_bib19","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/s41556-024-01360-8","article-title":"A guideline on the molecular ecosystem regulating ferroptosis","volume":"26","author":"Dai","year":"2024","journal-title":"Nat Cell Biol"},{"key":"2025080607064794600_bib20","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","article-title":"Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications","volume":"185","author":"Stockwell","year":"2022","journal-title":"Cell"},{"key":"2025080607064794600_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aaw9872","article-title":"Cysteine depletion induces pancreatic tumor ferroptosis in mice","volume":"368","author":"Badgley","year":"2020","journal-title":"Science"},{"key":"2025080607064794600_bib22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025080607064794600_bib23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","article-title":"The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions","volume":"42","author":"Lei","year":"2024","journal-title":"Cancer Cell"},{"key":"2025080607064794600_bib24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"2025080607064794600_bib25","doi-asserted-by":"crossref","first-page":"e001369","DOI":"10.1136\/jitc-2020-001369","article-title":"Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity","volume":"8","author":"Efimova","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025080607064794600_bib26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","article-title":"Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy","volume":"35","author":"Yang","year":"2023","journal-title":"Cell Metab"},{"key":"2025080607064794600_bib27","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ccell.2024.10.010","article-title":"Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance","volume":"42","author":"Lin","year":"2024","journal-title":"Cancer Cell"},{"key":"2025080607064794600_bib28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cmet.2024.11.012","article-title":"Itaconate transporter SLC13A3 confers immunotherapy resistance via alkylation-mediated stabilization of PD-L1","volume":"37","author":"Fan","year":"2025","journal-title":"Cell Metab"},{"key":"2025080607064794600_bib29","doi-asserted-by":"crossref","first-page":"e2315541121","DOI":"10.1073\/pnas.2315541121","article-title":"USP8-governed GPX4 homeostasis orchestrates ferroptosis and cancer immunotherapy","volume":"121","author":"Li","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025080607064794600_bib30","doi-asserted-by":"crossref","first-page":"216935","DOI":"10.1016\/j.canlet.2024.216935","article-title":"CRISPR\/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma","volume":"593","author":"Yao","year":"2024","journal-title":"Cancer Lett"},{"key":"2025080607064794600_bib31","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.21037\/tlcr-22-408","article-title":"Identification and validation of a ferroptosis-related prognostic risk-scoring model and key genes in small cell lung cancer","volume":"11","author":"Li","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"2025080607064794600_bib32","doi-asserted-by":"crossref","first-page":"860806","DOI":"10.3389\/fsurg.2022.860806","article-title":"Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma","volume":"9","author":"Xu","year":"2022","journal-title":"Front Surg"},{"key":"2025080607064794600_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","article-title":"CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4","volume":"40","author":"Liao","year":"2022","journal-title":"Cancer Cell"},{"key":"2025080607064794600_bib34","doi-asserted-by":"crossref","first-page":"eadg3049","DOI":"10.1126\/scitranslmed.adg3049","article-title":"Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer","volume":"15","author":"Li","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025080607064794600_bib35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"2025080607064794600_bib36","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"2025080607064794600_bib37","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"key":"2025080607064794600_bib38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"2025080607064794600_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"2025080607064794600_bib40","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat Commun"},{"key":"2025080607064794600_bib41","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"2025080607064794600_bib42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13148-020-00907-4","article-title":"Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancer","volume":"12","author":"Kim","year":"2020","journal-title":"Clin Epigenetics"},{"key":"2025080607064794600_bib43","doi-asserted-by":"crossref","first-page":"e02523","DOI":"10.7554\/eLife.02523","article-title":"Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis","volume":"3","author":"Dixon","year":"2014","journal-title":"Elife"},{"key":"2025080607064794600_bib44","doi-asserted-by":"crossref","first-page":"103271","DOI":"10.1016\/j.ebiom.2021.103271","article-title":"An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer","volume":"65","author":"Zhou","year":"2021","journal-title":"EBioMedicine"},{"key":"2025080607064794600_bib45","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"2025080607064794600_bib46","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"2025080607064794600_bib47","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2025080607064794600_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cytogfr.2021.01.006","article-title":"Hallmarks of aging and immunosenescence: connecting the dots","volume":"59","author":"Rodrigues","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"2025080607064794600_bib49","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"2025080607064794600_bib50","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"2025080607064794600_bib51","doi-asserted-by":"crossref","first-page":"e2311181","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy","volume":"6","author":"Aggarwal","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025080607064794600_bib52","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"2025080607064794600_bib53","doi-asserted-by":"crossref","first-page":"e008339","DOI":"10.1136\/jitc-2023-008339","article-title":"Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types","volume":"12","author":"Shen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025080607064794600_bib54","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41467-022-29026-9","article-title":"Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors","volume":"13","author":"Nikolos","year":"2022","journal-title":"Nat Commun"},{"key":"2025080607064794600_bib55","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025080607064794600_bib56","doi-asserted-by":"crossref","first-page":"10500","DOI":"10.1038\/ncomms10500","article-title":"Functional annotation of rare gene aberration drivers of pancreatic cancer","volume":"7","author":"Tsang","year":"2016","journal-title":"Nat Commun"},{"key":"2025080607064794600_bib57","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12916-022-02287-3","article-title":"Targeted therapies for cancer","volume":"20","author":"Zhou","year":"2022","journal-title":"BMC Med"},{"key":"2025080607064794600_bib58","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1158\/2767-9764.CRC-24-0065","article-title":"Impact of tumor-intrinsic molecular features on survival and acquired tyrosine kinase inhibitor resistance in ALK-positive NSCLC","volume":"4","author":"Nakazawa","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2025080607064794600_bib59","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/2767-9764.CRC-24-0360","article-title":"Targeting TREX1 induces innate immune response in drug-resistant small-cell lung cancer","volume":"4","author":"Murayama","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2025080607064794600_bib60","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/156652412799218868","article-title":"Genomic sequencing of key genes in mouse pancreatic cancer cells","volume":"12","author":"Wang","year":"2012","journal-title":"Curr Mol Med"},{"key":"2025080607064794600_bib61","doi-asserted-by":"crossref","first-page":"216351","DOI":"10.1016\/j.canlet.2023.216351","article-title":"Pleckstrin-2 promotes tumour immune escape from NK cells by activating the MT1-MMP-MICA signalling axis in gastric cancer","volume":"572","author":"Mao","year":"2023","journal-title":"Cancer Lett"},{"key":"2025080607064794600_bib62","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1158\/2159-8290.CD-19-0338","article-title":"Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11","volume":"9","author":"Lang","year":"2019","journal-title":"Cancer Discov"},{"key":"2025080607064794600_bib63","doi-asserted-by":"crossref","first-page":"e139434","DOI":"10.1172\/JCI139434","article-title":"TYRO3 induces anti-PD-1\/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis","volume":"131","author":"Jiang","year":"2021","journal-title":"J Clin Invest"},{"key":"2025080607064794600_bib64","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41589-019-0462-8","article-title":"Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death","volume":"16","author":"Kapralov","year":"2020","journal-title":"Nat Chem Biol"},{"key":"2025080607064794600_bib65","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025080607064794600_bib66","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2024.03.009","article-title":"The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"key":"2025080607064794600_bib67","doi-asserted-by":"crossref","first-page":"e2427073122","DOI":"10.1073\/pnas.2427073122","article-title":"A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity","volume":"122","author":"Zhang","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025080607064794600_bib68","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-024-00869-9","article-title":"Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers","volume":"21","author":"Cao","year":"2024","journal-title":"Nat Rev Urol"},{"key":"2025080607064794600_bib69","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/s41575-021-00486-6","article-title":"Cell death in pancreatic cancer: from pathogenesis to therapy","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025080607064794600_bib70","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","article-title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"2025080607064794600_bib71","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0268\/3632506\/crc-25-0268.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/8\/1288\/3639249\/crc-25-0268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/8\/1288\/3639249\/crc-25-0268.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T11:06:59Z","timestamp":1754478419000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/8\/1288\/764016\/Evaluation-of-Ferroptosis-as-a-Biomarker-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0268","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7968277","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29836672","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29836660","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29836663","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29836651","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29836681","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29836669","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29836657","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29836648","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29836654","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29836675","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29836678","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}